SEQUELLA, INC.

Company Information

Company Name
SEQUELLA, INC.
Address
9610 MEDICAL CENTER DR, STE 200
ROCKVILLE, MD, -
Phone
n/a
URL
n/a
DUNS
125129606
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$4,918,941.00
19
SBIR Phase II
$6,309,125.00
4
STTR Phase I
$587,856.00
1
Chart code to be here

Award List

  1. SQ109 for treatment of MDR-TB

    Amount: $599,797.00

    DESCRIPTION (provided by applicant): SQ109 is a small molecule, orally active drug and is a new drug candidate in clinical development for the treatment of all forms of tuberculosis (TB), including mu ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. N/A

    Amount: $300,000.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  3. SHIKIMATE ENZYMES AS NOVEL TUBERCULOSIS DRUG TARGETS

    Amount: $294,182.00

    Not Available The development of equipment that requires extensive fluid manipulation, such as analytical diagnostic tools, has generally lagged behind those of a purely electromechanical nature, eve ...

    SBIR Phase I 1999 Department of Health and Human Services
  4. COMMERCIAL DEVELOPMENT OF THE BRONX BOX

    Amount: $294,875.00

    Confirmation of a diagnosis of tuberculosis requires clear identification of the infecting organism. Historically, this has been accomplished by specific staining (i.e. acid fast staining, a ...

    SBIR Phase I 2001 Department of Health and Human Services
  5. A Rapid Lateral Flow Test for TB in Nonhuman Primates

    Amount: $162,215.00

    DESCRIPTION (provided by applicant): The goal of the research is to develop a rapid, lateral flow, antibody-based diagnostic test for tuberculosis (TB) in nonhuman primates. The unrelia ...

    SBIR Phase I 2001 Department of Health and Human Services
  6. Transdermal Test for Active Tuberculosis

    Amount: $232,038.00

    DESCRIPTION (provided by applicant):This proposal seeks to establish a development program to transition an experimental Transdermal Tuberculosis Skin Test into a commercial product ...

    SBIR Phase I 2001 Department of Health and Human Services
  7. A New Tuberculin for the Diagnosis of Tuberculosis

    Amount: $300,000.00

    DESCRIPTION (provided by applicant):Accurate diagnosis of tuberculosis (TB) infection is one of the pillars of effective TB control programs. The current tool to diagnose infection wit ...

    SBIR Phase I 2001 Department of Health and Human Services
  8. TRANSDERMAL, NON-INVASIVE MONITORING OF MEDICATION INGESTION

    Amount: $99,896.00

    N/A

    SBIR Phase I 2002 Department of Health and Human Services
  9. COMMERCIAL DEVELOPMENT OF THE BRONX BOX

    Amount: $1,064,900.00

    DESCRIPTION (provided by applicant): The World Health Organization (WHO) estimates that globally there are approximately 50 million people with multi-drug resistant tuberculosis (MDR-TB). Recognizing ...

    SBIR Phase II 2002 Department of Health and Human Services
  10. COMMERCIAL DEVELOPMENT OF THE BRONX BOX

    Amount: $0.00

    DESCRIPTION (provided by applicant): The World Health Organization (WHO) estimates that globally there are approximately 50 million people with multi-drug resistant tuberculosis (MDR-TB). Recognizing ...

    SBIR Phase I 2002 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government